Comparing Intrexon (XON) & Its Peers
Intrexon (NYSE: XON) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Intrexon to similar businesses based on the strength of its profitability, earnings, institutional ownership, risk, dividends, valuation and analyst recommendations.
Volatility & Risk
Intrexon has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Intrexon’s rivals have a beta of 1.55, indicating that their average stock price is 55% more volatile than the S&P 500.
This table compares Intrexon and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Intrexon||$190.93 million||-$186.61 million||-11.00|
|Intrexon Competitors||$217.29 million||-$39.39 million||-61.80|
Intrexon’s rivals have higher revenue and earnings than Intrexon. Intrexon is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
77.5% of Intrexon shares are held by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 55.1% of Intrexon shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Intrexon and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Intrexon and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon currently has a consensus target price of $38.50, suggesting a potential upside of 212.50%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.93%. Given Intrexon’s stronger consensus rating and higher possible upside, analysts plainly believe Intrexon is more favorable than its rivals.
Intrexon beats its rivals on 8 of the 12 factors compared.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.